Please select the option that best describes you:
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
How do you balance the therapeutic efficacy of CN with long term CKD risk from radical nephrectomy.